# US 2026/0259219 A1 · Measuring redox changes in plasma proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0259219 A1
- Document ID: US20260259219A1
- Status: Published application
- Kind: A1
- Application number: 19/164,019
- Filed: 2023-03-17
- Published: 2026-09-03
- Earliest claimed: 2023-03-17
- Assignees: Cancer Research Technology Limited
- Applicants: Cancer Research Technology Limited
- Inventors: Sara Rossana Zanivan; Sergio Lilla; Ulla-Maja Hagbo Bailey
- Web page: https://patentgrep.com/patent/US20260259219A1

## CPC

- G01N 33/57525: of the liver or pancreas
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 1/44: Sample treatment involving radiation, e.g. heat
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N 2440/20: formation of disulphide bridges
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided is a method for measuring proteomic cysteine redox status in a sample obtained from a bodily fluid of a subject, the method comprising: (i) providing said sample, wherein the sample comprises a plurality of different proteins that comprise cysteine residues, a proportion of which are in reduced form and a proportion of which are in reversibly oxidised form; (ii) contacting the sample with a first label that selectively labels the reduced cysteine thiols of the plurality of different proteins; (iii) contacting the sample with a reducing agent that reduces the reversibly oxidised cysteine residues to form reduced cysteine thiols; (iv) contacting the sample with a second label that labels the reduced cysteine thiols formed in step (iii), wherein the second label is distinguishable from the first label by mass spectrometry, (v) processing the sample for analysis by mass spectrometry; and (vi) analysing the sample by mass spectrometry to measure at least the relative abundance of identified peptides labelled with the first label and corresponding identified peptides labelled with the second label, thereby providing a measure of the proteomic cysteine redox status of the sample. The invention also provides related methods for biomarker discovery and for predicting presence of a liver disease and/or cancer, such as hepatocellular carcinoma (HCC) in a subject.

## Claims

### Claim 1

A method for measuring proteomic cysteine redox status in a sample obtained from bodily fluid of a subject, the method comprising:
(i) providing said sample, wherein the sample comprises a plurality of different proteins that comprise cysteine residues, a proportion of which are in reduced form and a proportion of which are in reversibly oxidised form;
(ii) contacting the sample with a first label that selectively labels the reduced cysteine thiols of the plurality of different proteins;
(iii) contacting the sample with a reducing agent that reduces the reversibly oxidised cysteine residues to form reduced cysteine thiols;
(iv) contacting the sample with a second label that labels the reduced cysteine thiols formed in step (iii), wherein the second label is distinguishable from the first label by mass spectrometry,
(v) processing the sample for analysis by mass spectrometry; and
(vi) analysing the sample by mass spectrometry to measure at least the relative abundance of identified peptides labelled with the first label and corresponding identified peptides labelled with the second label, thereby providing a measure of the proteomic cysteine redox status of the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample has been obtained from a circulating bodily fluid.

### Claim 3 (depends on 2)

The method of claim 2, wherein the circulating bodily fluid is selected from: a plasma sample, a blood sample, a circulating exosome-containing liquid sample, a cerebrospinal fluid sample and a lymphatic fluid sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein said sample has been obtained from ascites or pleural effusion.

### Claim 5

The method of any one of the preceding claims, wherein said sample is heated to a temperature of greater than 50° C., optionally greater than 90° C., for a period of time sufficient to increase protein denaturation prior to or current with contacting the sample with said first label.

### Claim 6

The method of any one of the preceding claims, wherein said first label is selected from: iodoacetamide-light (“IAA-light”), n-ethylmaleimide (NEM), and heavy stable isotope-labelled iodoacetamide (“IAA-heavy”).

### Claim 7

The method of any one of the preceding claims, wherein said second label is selected from: IAA-heavy, IAA-light and n-ethylmaleimide (NEM), provided that said second label differs from said first label.

### Claim 8

The method of any one of the preceding claims, wherein said first label comprises IAA-light and said second label comprises IAA-heavy.

### Claim 9

The method of any one of the preceding claims, wherein said reducing agent comprises dithiothreitol (DTT).

### Claim 10

The method of any one of the preceding claims, wherein said sample is solubilised by contacting with sodium deoxycholate (SDC) prior to or during step (ii).

### Claim 11

The method of any one of the preceding claims, wherein said sample is contacted with magnetic beads, optionally SpeedBead Magnetic Carboxylate (SP3 beads), prior to or during step (v).

### Claim 12

The method of any one of the preceding claims, wherein the method further comprises contacting the sample with at least one tandem mass tag (TMT) to enable multiplexing of said mass spectrometry analysis.

### Claim 13

The method of any one of the preceding claims, wherein the concentration of said second label in step (iv) is higher than the concentration of said first label in step (ii).

### Claim 14 (depends on 13)

The method of claim 13, wherein the first label comprises IAA-light at a concentration during labelling of between 0.015M and 0.025M, optionally at 0.02M, and wherein the second label comprises IAA-heavy at a concentration during labelling of between 0.03M and 0.05M, optionally at 0.04M.

### Claim 15 (depends on 14)

The method of claim 14, wherein the reducing agent comprises DTT at a concentration during the reducing step of between 0.025M and 0.045M, optionally at 0.033M.

### Claim 16

The method of any one of the preceding claims, wherein said processing of step (v) comprises at least one of: enzymatic digestion of the proteins in the sample, acidification of the sample, and peptide fractionation of the sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein said enzymatic digestion is trypsin digestion.

### Claim 18

The method of any one of the preceding claims, wherein the mass spectrometry (MS) comprises ultra-high performance liquid chromatography-MS/MS (UHPLC-MS/MS).

### Claim 19

The method of any one of the preceding claims, wherein step (vi) further comprises calculating, for each of a plurality of cysteine residues, the proportion that was in reversibly oxidised form in the sample.

### Claim 20

The method of any one of the preceding claims, wherein step (vi) further comprises deriving at least one statistical measure, optionally a z-score, for the degree of cysteine oxidation of each of a plurality of non-identical peptides.

### Claim 21

The method of any one of the preceding claims, wherein said plurality of different proteins comprises at least 50, 100, 500, or at least 1000.

### Claim 22

The method of any one of the preceding claims, wherein said sample is of less than 100 μl, less than 50 μl, less than 10 μl, less than 1 μl or less than 100 nl when obtained from the subject.

### Claim 23

The method of any one of the preceding claims, wherein the method further comprises normalising the measure of identified peptides labelled with the first label and/or the measure of identified peptides labelled with the second label for protein abundance.

### Claim 24 (depends on 23)

The method of claim 23, wherein said normalising comprises normalising for the level of the corresponding cysteine-containing protein in the sample as determined by mass spectrometry.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for identifying biomarkers that are significantly associated with a particular disease state, for identifying biomarkers that are predictive of response to a treatment and/or for identifying biomarkers for monitoring disease progression, the method comprising:
performing the method of any one of claims 1 to 24 on a plurality of samples obtained from subjects known not to have the particular disease state (“controls”) and on a plurality of samples obtained from subjects known to have the particular disease state (“diseased subjects”) and thereby determining the proteomic cysteine redox status of the controls and the diseased subjects for a plurality of proteins and/or peptides;
comparing the proteomic cysteine redox status of the controls and the diseased subjects to identify proteins and/or peptides that are significantly oxidised or reduced in the samples from the diseased subjects as compared with the samples from the controls, thereby identifying these proteins and/or peptides as biomarkers of the particular disease state.

### Claim 26 (depends on 25)

The method of claim 25, wherein the subjects known not to have the particular disease state have a different disease or have the same disease as the particular disease state, but are at a different disease stage.

### Claim 27 (depends on 25)

The method of claim 25, wherein the subjects known not to have the particular disease state are healthy controls.

### Claim 28 (depends on 25)

The method of claim 25, wherein the particular disease state is a liver disease and/or a cancer.

### Claim 29 (depends on 26)

The method of claim 26, wherein the particular disease state is early-stage hepatocellular carcinoma (HCC).

### Claim 30 (depends on 29)

The method of claim 29, wherein the subjects known not to have the particular disease state are subjects who are known to have liver cirrhosis without HCC; are subjects who are known to have hepatitis B without HCC; and/or are subjects who are known to have hepatitis C without HCC.

### Claim 31 (depends on 30)

The method of claim 30, wherein the particular disease state is a metastatic cancer of known primary and the subjects known not to have the particular disease state have a cancer, optionally a metastatic cancer, of a primary source that differs from said known primary of the particular disease state.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for determining that a subject is likely to have hepatocellular carcinoma (HCC), optionally early-stage HCC, the method comprising:
performing the method of any one of claims 1 to 24 on a bodily fluid sample obtained from the subject thereby determining the proteomic cysteine redox status of the sample for a plurality of proteins and/or peptides;
providing data that represents the proteomic cysteine redox status of the sample for the plurality of proteins and/or peptides to a machine learning classifier, wherein said classifier has been trained on a training dataset that comprises proteomic cysteine redox status for the same plurality of proteins and/or peptides from both subjects known to have HCC and subjects known not to have HCC;
causing the machine learning classifier to classify the sample as belonging to the HCC class or not the HCC class based on the provided proteomic cysteine redox status of the sample; and
outputting the classification to a user.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subject has, or is suspected to have, liver cirrhosis.

### Claim 34 (depends on 32, 33)

The method of claim 32 or claim 33, wherein the machine learning classifier has been trained on a training data set that comprises proteomic cysteine redox status from subjects known to have early-stage HCC and subjects known to have liver cirrhosis without HCC.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32 to 34, wherein the machine learning classifier comprises a processor and non-transitory memory comprising instructions that when run by the processor cause the processor to process the data representing the proteomic cysteine redox status of the sample for the plurality of proteins and/or peptides according to a learnt model and to output a probabilistic classification of HCC or non-HCC.

### Claim 36 (depends on 35)

The method of claim 35, wherein the learnt model is selected from: a decision tree, a logistic regression model, an artificial neural network, a support vector machine (SVM), naïve bayes or k-nearest neighbour algorithm, optionally wherein the decision tree comprises a gradient boosting algorithm or a random forest algorithm.

### Claim 37 (depends on 32, 33, 34, 35, 36)

The method of any one of claims 32 to 36, wherein said plurality of proteins and/or peptides comprises at least 5, 10, 15 or at least 20 proteins, or cysteine-containing peptide fragments thereof, selected from: GC, ALB, IGFALS, SERPIND1, AZGP1, PLG, IGKC, CD5L, TF, C7, IGHG1, CFB, IGHG3, APOB, SERPINC1, F2, C1S, CP, CD5L, APOH, AMBP, PLG, and HP.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The method of any one of claims 32 to 37, wherein said plurality of proteins and/or peptides comprises at least 5, 10, 15, 20 or all of the peptides set forth in SEQ ID NOs: 114-152.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 32 to 38, wherein the machine learning classifier is also provided with one or more additional biomarker measurements, optionally protein abundance measurements, obtained from the sample, and wherein the machine learning classifier has been trained on a training data set that further comprises the one or more additional biomarker measurements from both subjects known to have HCC and subjects known not to have HCC.

### Claim 40 (depends on 39)

The method of claim 39, where the one or more additional biomarker measurements comprise: the blood level of alpha-fetoprotein (AFP) and/or any one of the proteins shown in FIG. 10.
